Innocenti Giulio R, Wadei Hani M, Prieto Mikel, Dean Patrick G, Ramos Eduardo J, Textor Stephen, Khamash Hasan, Larson Timothy S, Cosio Fernando, Kosberg Kay, Fix Lynette, Bauer Charise, Stegall Mark D
William J. von Liebig Transplant Center, Mayo Clinic and Foundation, Rochester, MN, USA.
Transplantation. 2007 Jan 27;83(2):144-9. doi: 10.1097/01.tp.0000250555.46539.65.
Preemptive kidney transplantation (prior to the institution of dialysis) avoids the morbidity and mortality of dialysis; however, detailed studies of high-risk patients are lacking. The aim of the current study was to compare recent outcomes of preemptive (P) versus nonpreemptive (NP) living donor kidney transplantation with an emphasis on high-risk recipients.
We retrospectively analyzed 438 sequential solitary living donor kidney transplants at our institution between January 2000 and December 2002. In all, 44% were preemptive. NP recipients were dialyzed for 21+/-36 months (range 1-312 months).
Overall, three-year patient survival was similar in the NP and P groups. When stratified by diabetes and age >65 years, P and NP recipients again showed similar survival. Death-censored three-year graft survival was better in the P group (97% vs. 90%, P=0.01), but was not significant by multivariate analysis. Delayed graft function was more frequent in NP vs. P (10% vs. 4%; P=0.01), but other early complications were similar including: acute rejection, 16% vs. 11% (P=0.11); primary nonfunction, 3% vs. 2% (P=0.38); and wound complications, 19% vs. 17% (P=0.54). Glomerular filtration rate at three years was similar in the two groups (53+/-23 preemptive vs. 52+/-20 ml/min nonpreemptive; P=0.37).
With prompt referral and workup, preemptive kidney transplantation can be performed successfully in a large percentage of renal allograft recipients. Preemptive transplantation avoids unnecessary dialysis and should be emphasized as initial therapy for many patients with end-stage renal disease.
抢先肾移植(在开始透析之前)可避免透析带来的发病率和死亡率;然而,缺乏对高危患者的详细研究。本研究的目的是比较抢先(P)与非抢先(NP)活体供肾移植的近期结果,重点关注高危受者。
我们回顾性分析了2000年1月至2002年12月在我院进行的438例连续的单例活体供肾移植。其中,44%为抢先移植。NP受者透析了21±36个月(范围1 - 312个月)。
总体而言,NP组和P组的三年患者生存率相似。按糖尿病和年龄>65岁分层时,P组和NP组受者的生存率再次相似。P组的死亡删失三年移植物生存率更好(97%对90%,P = 0.01),但多因素分析无显著性差异。NP组与P组相比,移植肾功能延迟更常见(10%对4%;P = 0.01),但其他早期并发症相似,包括:急性排斥反应,16%对11%(P = 0.11);原发性无功能,3%对2%(P = 0.38);以及伤口并发症,19%对17%(P = 0.54)。两组三年时的肾小球滤过率相似(抢先组53±23对非抢先组52±20 ml/分钟;P = 0.37)。
通过及时转诊和检查,大部分肾移植受者可成功进行抢先肾移植。抢先移植可避免不必要的透析,应作为许多终末期肾病患者的初始治疗方法加以强调。